TiumBio Co., Ltd. (KOSDAQ:321550)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,685.00
-320.00 (-7.99%)
At close: Jun 26, 2026
Market Cap126.31B -22.9%
Revenue (ttm)13.13B +90.1%
Net Income-14.87B
EPS-536.69
Shares Out 30.04M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume313,742
Open3,900.00
Previous Close4,005.00
Day's Range3,540.00 - 4,005.00
52-Week Range3,540.00 - 13,700.00
Beta-0.56
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 321550
Full Company Profile

Financial Performance

In 2025, TiumBio's revenue was 12.29 billion, an increase of 80.92% compared to the previous year's 6.79 billion. Losses were -17.36 billion, -15.90% less than in 2024.

Financial Statements